Akari therapeutics plc (AKTX)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Cash Flows from Operating Activities:
Net loss

-35,399

-18,140

-45,317

-1,947

-3,620

-4,268

-2,119

-675

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

-

-

-

-

2

2

0

0

Depreciation and amortization

42

39

10

4

-

-

-

-

Stock-based compensation

2,734

3,933

1,039

0

94

514

140

0

Litigation settlement loss

-2,700

0

0

-

-

-

-

-

Compensation expense

0

0

750

0

-

-

-

-

Amortization of debt discount

0

0

3,031

0

-

-

-

-

Excess consideration

0

0

19,283

0

-

-

-

-

Financing expense

0

0

22,973

0

-

-

-

-

Changes in fair value of the liability for options and warrants

2,581

8,733

11,408

0

-

-

-

-

Foreign currency exchange (gains) loss

-93

272

0

-

-

-

-

-

Foreign currency exchange gains

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Increase in assets:
Changes in values of liability related to stock options and warrants

-

-

-

-

286

418

120

95

Prepaid expenses and other current assets

-807

785

-913

8

161

-7

-4

-14

(Decrease) increase in liabilities:
Accounts payable and accrued expenses

12

-671

3,755

474

-

-

-

-

Other liabilities

-8

7

3

0

-

-

-

-

Total adjustments

3,800

-6,483

40,351

470

-

-

-

-

Net Cash Used in Operating Activities

-

-

-

-1,476

-

-

-

-

(Decrease) increase in trade payables

-

-

-

-

-1,045

627

612

237

Decrease in other accounts payable

-

-

-

-

-676

394

475

181

Increase in other long term liabilities

-

-

-

-

0

0

-

-

Accrued interest expenses and issuance costs

-

-

-

-

242

1,008

0

0

Net Cash Used in Operating Activities

-31,598

-24,624

-4,965

-

-5,450

-2,134

-1,008

-366

Cash Flows from Investing Activities:
Purchase of property and equipment

36

54

10

0

0

0

0

0

Cash received from reverse acquisition

0

0

1,410

0

-

-

-

-

Purchase of short-term investments

0

46,120

0

0

-

-

-

-

Redemption of short-term investments

10,021

36,098

0

0

-

-

-

-

Receivable from related party

0

10

-8

0

-

-

-

-

Net Cash Provided by (Used In) Investing Activities

-

-

-

0

-

-

-

-

Proceeds from shareholder loans

0

0

3,031

432

-

-

-

-

Repayment of shareholder loans

0

0

3,561

0

-

-

-

-

Proceeds from issuance of convertible notes and warrants, net

-

-

-

-

0

890

0

0

Repayment of convertible notes

-

-

-

-

1,100

0

-

-

Proceeds from issuance of shares

17,400

0

75,000

3,690

0

118

75

60

Share issuance costs

1,728

0

5,425

0

-

-

-

-

Proceeds from stock subscription

-

-

-

112

-

-

-

-

Net Cash Used in Financing Activities

-

-

-

4,235

-

-

-

-

Investment in short term restricted deposit

-

-

-

-

0

0

-

-

Net Cash (Used in) Provided by Investing Activities

9,985

-10,066

1,391

-

0

0

0

0

Proceeds from issuance of shares, net

-

-

-

-

13,103

2,224

930

312

Net Cash Provided by Financing Activities

15,671

0

69,044

-

12,003

3,232

1,005

372

Effect of Exchange Rates on Cash

-50

-130

121

15

-

-

-

-

Net Decrease in Cash

-5,992

-34,821

65,592

2,773

6,553

1,098

-3

6

Interest

-

-

-

5

-

-

-

-

Expiration of deferred shares

-

-

-

-

-

-

420

0

Director fee waiver

-

-

-

-

-

-

73

0

Classification of warrants from liability to equity as a result of modification

-

-

-

-

-

-

0

0

Classification of warrants from liability to equity as a result of utilization and expiration of most favored nation terms

-

-

-

-

-

-

0

0

Purchase of property and equipment

-

-

-

-

-

-

0

0

Disposal of property and equipment

-

-

-

-

-

-

0

-

Conversion of trade payables into warrants

-

-

-

-

-

-

0

0

Interest

0

0

22

-

-

-

-

-